China’s NMPA approved Innovent Biologics’ Tabosun (ipilimumab IBI‑310) in combination with sintilimab as a neoadjuvant treatment for resectable MSI‑high or mismatch repair‑deficient colon cancer. Separately, Hutchmed received NMPA acceptance and priority review for fanregratinib (HMPL‑453), an FGFR‑targeted therapy for intrahepatic cholangiocarcinoma based on a single phase II registration study. Regulatory context: Innovent’s approval supports combination checkpoint blockade in a defined genetic subset of colon cancer; the NMPA’s priority review for Hutchmed reflects willingness to consider single‑arm phase II data for oncology drugs addressing high unmet need. For readers: MSI‑high (microsatellite instability‑high) denotes tumors with mismatch repair deficiency that are more likely to respond to immune checkpoint inhibitors. Why it matters: both moves highlight the NMPA’s evolving regulatory flexibility for oncology and the accelerating pathway for domestically developed cancer therapies in China’s market.